Komal Jhaveri, MD, FACP

Komal Jhaveri, MD, FACP, is the section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center

Articles

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

Dr. Jhaveri on the TUXEDO-1 Trial in HER2+ Breast Cancer With Brain Metastases

March 23rd 2022

Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Dr. Jhaveri on Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 21st 2022

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates

February 3rd 2022

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.

ADC Therapies in Development in Breast Cancer

February 3rd 2022

An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.

Sacituzumab Govitecan Safety Profile in TNBC

January 28th 2022

Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.

Sacituzumab Govitecan for TNBC

January 28th 2022

Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.

Managing Patients With MBC on T-DXd Therapy

January 21st 2022

Strategies used to help monitor and manage T-DXd treatment-related adverse events.

T-DXd for HER2+ Metastatic Breast Cancer

January 21st 2022

Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

November 5th 2020

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Dr. Jhaveri on the Use of Trastuzumab Biosimilars in Breast Cancer

November 8th 2019

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.